2025年以来，北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技公司"）大力推动重点科研项目攻关，在新药研发、上市品种临 床研究，以及学术论文发表、行业标准制定等相关领域接连步入新阶段。企业以市场需求为导向、以科研创新为驱动的发展模式频结硕 果，老字号中药企业的核心竞争力正从传统工艺向现代科研证据体系延伸。 同仁堂科技公司聚焦上市品种的持续深耕更是成果丰硕，多项针对名优品种的临床研究步入收获期。金匮肾气丸完成了针对"肾阳虚证夜 尿频多"的临床研究，为这一经典名方治疗特定症状提供了新的临床证据。感冒清热颗粒完成了治疗普通感冒（风寒证）的有效性和安全 性临床研究，进一步明确了其适用人群和疗效特点。此外，六味地黄类方治疗糖尿病视网膜病变的药效机制研究、永盛合阿胶治疗肿瘤 相关性贫血的真实世界研究等也已完成，系统揭示了传统方药在现代疾病治疗中的科学内涵。在基础研究层面，同仁堂科技公司对加味 逍遥丸、京制牛黄解毒片等品种的药效物质基础和作用机制研究取得关键突破，致力于"讲清楚、说明白"中药为什么有效。 从衡量企业科研实力的一个重要维度——高质量论文发表来看，15篇高水平论文发表，其中3篇为SCI论文，不仅展现了公司 ...

Group 1 - The core activity is a series of public welfare events initiated by Tongrentang Technology Company and Beijing Youth Daily, focusing on integrating traditional Chinese medicine (TCM) culture into rural revitalization efforts [1][21] - The events include winter health consultations and TCM cultural experience activities, aimed at promoting health and wellness through TCM knowledge [1][10] - The activities are designed to be engaging and educational, featuring hands-on experiences such as making traditional Chinese medicine pills and learning about herbal identification [3][5] Group 2 - In the community, TCM lectures cover winter health tips, dietary recommendations, and acupoint massage techniques, helping residents understand TCM practices [12][14] - The events also include interactive experiences, such as creating aromatic bracelets, which enhance community engagement with TCM culture [15] - Health consultations provided by experts from Tongrentang and Beijing University of Chinese Medicine address residents' health concerns, offering personalized advice and treatments [17][19] Group 3 - A separate initiative focuses on children with autism, providing TCM cultural experiences and health consultations tailored to their needs [21][23] - The program includes donations of essential rehabilitation materials and aims to improve the well-being of special needs children through TCM therapies [21][23] - The immersive activities allow participants to experience TCM culture through multiple senses, fostering a deeper appreciation for its benefits [23]

Core Viewpoint - The article discusses the investigation and actions taken against Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. regarding the "Antarctic Krill Oil Gel Candy" incident, emphasizing the company's commitment to consumer rights and brand protection [2][4]. Group 1: Investigation and Actions - The Chengdu New District Market Supervision Administration has established a joint investigation team to look into the "Antarctic Krill Oil" issue and has filed a case against the involved company [2]. - Beijing Tongrentang Group has issued an apology and initiated a zero-tolerance brand management action, including a comprehensive investigation of the involved products [4][5]. - The company has ordered the immediate removal of the implicated products from the market and is ensuring compensation for consumers as per regulatory requirements [5][6]. Group 2: Brand Protection Measures - The company is conducting a thorough review of brand usage across its subsidiaries to identify any illegal or non-compliant practices [7]. - A brand cleanup initiative is underway to eliminate improper use of the "Tongrentang" name and trademark, reinforcing brand management standards [8]. - The company is also standardizing the branding of authorized e-commerce platforms to help consumers accurately identify legitimate purchasing channels [9]. Group 3: Company Background and Product Assurance - Beijing Tongrentang has clarified that the implicated company, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., is a subsidiary of its controlling shareholder and is not directly under its management [11]. - The company focuses on the production and sale of traditional Chinese medicine, with over 400 product specifications covering various medical fields [11].

Core Viewpoint - The company is taking immediate and strict actions to protect its brand and consumer rights in response to allegations of false advertising related to a product marketed under its name. Group 1: Brand Protection Measures - The company has initiated a zero-tolerance brand management action, which includes legal accountability for trademark infringement against Sichuan Health, Habo Pharmaceutical, and related e-commerce platforms for misleading consumers [1] - A comprehensive investigation into brand usage violations across all subsidiaries is being conducted to ensure compliance with brand management standards [1] - The company is enforcing strict regulations on e-commerce platform store identifiers to ensure accurate representation of its brand and products [1] Group 2: Response to Allegations - Following allegations of false labeling of a product claiming to contain high levels of phospholipids, the company clarified that the involved entity, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., is not a subsidiary of the company [4] - The company has dispatched a special task force to Sichuan to conduct a thorough investigation into the product in question and has mandated the immediate removal of the product from shelves [5] - The company emphasizes that it focuses on the production and sale of its own pharmaceutical products, with no outsourcing to third parties, ensuring the integrity of its offerings [9]

Core Viewpoint - Beijing Tongrentang Group issued an apology regarding the Antarctic krill oil incident, emphasizing a zero-tolerance policy towards brand management and consumer protection [1][2]. Group 1: Company Actions - The company has initiated a special task force to conduct a thorough investigation of the involved products in Sichuan, ensuring a comprehensive inquiry [2]. - The company has ordered the immediate removal of the implicated products from the market and is supervising compliance with regulatory requirements for consumer compensation [2]. - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [2][3]. Group 2: Brand Protection Measures - The company is conducting a comprehensive review of brand usage to identify any illegal or non-compliant practices across its subsidiaries [2]. - A brand cleanup initiative is underway to eliminate improper use of the "Tongrentang" name and ensure strict adherence to brand management standards [2]. - The company is standardizing e-commerce platform store identifiers to ensure the correct use of the "Tongrentang" double-dragon logo, guiding consumers to recognize legitimate purchasing channels [3]. Group 3: Incident Background - A product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to falsely claim high phospholipid content, with testing revealing a phospholipid content of 0% [3]. - The implicated product was produced by Anhui Habao Pharmaceutical Co., Ltd., and distributed by Sichuan Tongrentang Health Pharmaceutical Co., Ltd., which is a subsidiary of Beijing Tongrentang Group [3][7]. - The company clarified that Sichuan Tongrentang Health Pharmaceutical is not a direct subsidiary of Beijing Tongrentang but is under the control of its parent company [7].

Core Viewpoint - Beijing Tongrentang Group issued an apology regarding the Antarctic krill oil incident, emphasizing a zero-tolerance policy towards brand management and consumer protection [2][3]. Group 1: Actions Taken by the Company - A special task force has been dispatched to Sichuan to conduct a thorough investigation of the involved products [3]. - The company has ordered the immediate removal of the implicated products from the market and will ensure compensation to consumers as per regulatory requirements [4]. - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [4]. - Accountability measures will be implemented for Sichuan Health and its parent company regarding operational and management issues [4]. Group 2: Brand Protection Initiatives - A comprehensive review of brand usage violations across all subsidiaries will be conducted [5]. - A brand cleanup initiative will be launched to eliminate improper use of the "Tongrentang" name and ensure compliance with brand management standards [6]. - E-commerce platform stores will be required to strictly use the "Tongrentang" double-dragon logo to help consumers identify legitimate purchasing channels [7]. Group 3: Incident Background - A product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to falsely claim high phospholipid content, with actual testing revealing a phospholipid content of 0% [7]. - The implicated product was produced by Anhui Habao Pharmaceutical and distributed by Sichuan Tongrentang Health, which is not a direct subsidiary of Beijing Tongrentang [7][10]. - The company clarified that it focuses on the production and sale of traditional Chinese medicine, with over 400 product specifications, and does not outsource production to third parties [10].

Core Viewpoint - The investor research event held by Tongrentang Technology showcased the company's commitment to modernizing traditional Chinese medicine while maintaining its heritage and quality standards [1][3]. Group 1: Production and Technology - The production line at Tongrentang Technology employs automated and connected processes, ensuring a standardized, controllable, and efficient production of traditional Chinese medicine products [3]. - The company is actively investing in new equipment and technologies to build a modern intelligent manufacturing system for traditional Chinese medicine, aiming for high-quality, traceable products [3]. Group 2: Management Communication - During the event, the management team, led by General Manager Zhang Chunyou, engaged in in-depth discussions with investors regarding the company's strategic direction, core product layout, capacity enhancement, and future growth opportunities [4]. - The management emphasized the systemic development opportunities in the traditional Chinese medicine industry, driven by national health strategies and policies, and the company's commitment to deepening its presence in this field [4]. Group 3: Investor Relations - The event served as a platform for investor relations management, highlighting the importance of transparent and proactive communication between the company and its investors [5]. - Tongrentang Technology aims to create an open and inclusive investor relations ecosystem, reflecting its strategic determination and commitment to product value [5].

Core Viewpoint - The investor research event held by Tong Ren Tang Technology showcased the company's commitment to modernizing traditional Chinese medicine while maintaining its heritage and quality standards [1][2]. Group 1: Production and Innovation - The production line at Tong Ren Tang Technology employs automated and connected processes, ensuring efficiency and quality in the manufacturing of traditional Chinese medicine products [2]. - The company is focused on upgrading its production capabilities and implementing new technologies to create a modern intelligent manufacturing system for traditional Chinese medicine [2]. - The goal is to ensure that every pill produced meets high-quality standards and is traceable, embodying the spirit of Tong Ren Tang in a modern factory setting [2]. Group 2: Management Communication and Strategy - During the event, the management team, led by General Manager Zhang Chunyou, engaged in detailed discussions with investors regarding the company's operational strategy, product positioning, and future growth opportunities [3]. - The management emphasized the systemic development opportunities in the traditional Chinese medicine industry, driven by national health strategies and policies [3]. - Tong Ren Tang Technology aims to leverage its brand, technology, and quality advantages to deepen its focus on traditional Chinese medicine and explore new growth avenues in health management [3]. Group 3: Investor Relations - The research event served as a platform for enhancing investor relations, with the management team expressing the importance of transparent communication with investors [4]. - The company is committed to maintaining an open and inclusive investor relations ecosystem, reflecting its strategic determination and proactive approach in the industry [4]. - Continuous and transparent communication is seen as a vital bridge connecting the company with long-term value investors [4].

Core Insights - The investor research event held on December 16 at Tong Ren Tang Technology Development Co., Ltd. showcased the company's modernization efforts and commitment to traditional craftsmanship in the context of its transformation [1] Group 1: Production and Technology - The production line at Tong Ren Tang employs automated and connected processes, ensuring a seamless workflow from pill production to packaging, highlighting the integration of traditional methods with modern technology [4] - The company aims to establish a modern intelligent manufacturing system for traditional Chinese medicine, ensuring that each pill maintains high quality and traceability [4] Group 2: Management Communication - During the event, the management team, led by General Manager Zhang Chunyou, engaged in detailed discussions with investors regarding the company's operational strategy, core product layout, capacity enhancement, and future growth potential [4] - The management emphasized the importance of transparent communication with investors to convey the company's cultural values, operational logic, and strategic planning [5] Group 3: Industry Context - The Chinese medicine industry is perceived to be entering a systematic development opportunity, supported by national health strategies and policies promoting traditional medicine [5] - Tong Ren Tang is positioned to leverage its brand, technology, and quality systems to deepen its engagement in the traditional medicine sector and explore new growth avenues [5]

Group 1 - The core issue involves a false labeling incident related to Antarctic krill oil, where the company Beijing Tong Ren Tang Sichuan Health Pharmaceutical Co., Ltd. is incorrectly identified as a subsidiary of Beijing Tong Ren Tang Co., Ltd. [1][2] - Beijing Tong Ren Tang Co., Ltd. clarified that it is focused on the production and sales of pharmaceuticals, with no external third-party production involved [1][2] - As of December 17, the total market value of Beijing Tong Ren Tang Co., Ltd. is approximately 44.67 billion yuan [1] Group 2 - The Shanghai Consumer Protection Commission reported a potential fraud case involving a product labeled as "Beijing Tong Ren Tang 99% High Purity Antarctic Krill Oil," which claimed high phospholipid content but was found to have none [2] - The product in question is produced by Anhui Habao Pharmaceutical Co., Ltd. and distributed by Beijing Tong Ren Tang Sichuan Health Pharmaceutical Co., Ltd. [2]